Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.

NCT00528567 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00528567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00528567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
June 30, 2014
Enrollment
2,591 (actual)
Sites
403

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer